Practice Areas - Corporate and M&A Law Firms and Lawyers
| Deal Date: | 13-08-2013 | Practice Area: | Corporate and M&A |
| Deal Title: | NRW.BANK.Venture Fonds Zwei Investment in CAP-CMV | Industry: | Pharmaceuticals & Biotechnology |
| Description: |
CAP-CMV GmbH, a company focusing exclusively on the development of a novel vaccine protecting against human Cytomegalovirus (HCMV) infection, has announced that it has raised a seed financing round of EUR0.8 million led by Peppermint VenturePartners via the new Charite Biomedical Fund. Additional financing was provided by NRW.BANK, Creathor Venture, KfW and private investors. CAP-CMV GmbH is a spin-out of CEVEC Pharmaceuticals GmbH, a biopharmaceutical company specialised in developing and producing therapeutic proteins, vaccines and monoclonal antibodies with human glycosylation patterns.
SJ Berwin advised Peppermint VenturePartners and NRW.BANK.Venture Fonds Zwei on this seed financing. Advice was provided by partner Frank Vogel as well as associates Sabine Roth and Lea Irmisch.
|
||
| Financial Center: | Berlin | Value: | 0.00-100.00 |
| Advised Party: | Private Equity Investor | Law Firm | King & Wood Mallesons SJ Berwin |
| Target Company Jurisdiction | Germany | Acquiror Jurisdiction | Germany |
| Classification: |
Financial Buyer Acquisitions Minority Investment |
Lawyer | Frank Vogel |
